Modera Wealth Management LLC Sells 8,207 Shares of CVS Health Co. (NYSE:CVS)

Modera Wealth Management LLC trimmed its position in shares of CVS Health Co. (NYSE:CVS) by 15.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,622 shares of the pharmacy operator’s stock after selling 8,207 shares during the period. Modera Wealth Management LLC’s holdings in CVS Health were worth $2,048,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CVS. Widmann Financial Services Inc. boosted its stake in shares of CVS Health by 1.8% during the third quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock valued at $724,000 after purchasing an additional 200 shares during the period. Manchester Capital Management LLC lifted its holdings in CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock valued at $200,000 after buying an additional 204 shares in the last quarter. Rogco LP boosted its position in CVS Health by 3.2% in the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock valued at $303,000 after buying an additional 210 shares during the period. Hazlett Burt & Watson Inc. grew its stake in CVS Health by 9.8% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,575 shares of the pharmacy operator’s stock worth $163,000 after acquiring an additional 229 shares in the last quarter. Finally, Glass Jacobson Investment Advisors llc raised its stake in shares of CVS Health by 26.8% during the third quarter. Glass Jacobson Investment Advisors llc now owns 1,220 shares of the pharmacy operator’s stock valued at $77,000 after acquiring an additional 258 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 1.4 %

CVS Health stock opened at $64.82 on Tuesday. CVS Health Co. has a one year low of $43.56 and a one year high of $80.75. The stock has a market cap of $81.72 billion, a PE ratio of 17.71, a price-to-earnings-growth ratio of 0.98 and a beta of 0.61. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The stock has a 50-day moving average of $54.74 and a two-hundred day moving average of $56.53.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.10%. CVS Health’s dividend payout ratio is currently 72.68%.

Insider Buying and Selling at CVS Health

In other news, Director Michael F. Mahoney bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.24% of the company’s stock.

Wall Street Analyst Weigh In

CVS has been the topic of several research analyst reports. Argus set a $77.00 price objective on CVS Health in a research note on Tuesday, February 18th. Wells Fargo & Company increased their price target on CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $55.00 to $75.00 in a report on Thursday, February 13th. TD Cowen increased their target price on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, UBS Group lowered their price target on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.